EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

A Multipart Phase 1 Study to Assess Safety and Pharmacokinetics of Ibuzatrelvir in Healthy Participants and Dose Selection for a Dose‐Ranging Study

Ravi Shankar P Singh iD, Sima S Toussi, Frances Hackman iD, Mona Shahbazi iD, John Prybylski iD, Siddhee A Sahasrabudhe iD, Penelope Crownover, Eugene P Kadar iD, Billy T George iD, Negar Niki Alami iD, Arthur Bergman

Clinical and Translational Science · 2026

DOI: 10.1111/cts.70659 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Clinical and Translational Science, 2026. Verfasst von Ravi Shankar P Singh und 10 weiteren Autor:innen. Beteiligte Einrichtung: Pfizer Research and Development, Cambridge, Massachusetts, USA. Hauptthemen laut MEDLINE: Antiviral Agents, COVID-19 Drug Treatment, SARS-CoV-2. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

COVID‐19 continues to be a threat to global health and a burden on healthcare systems. There is an ongoing need for COVID‐19 antiviral therapies that are safe and effective across broad patient populations. Ibuzatrelvir is a potent, selective inhibitor of the SARS‐CoV‐2 main protease and demonstrated favorable properties for clinical development. We report safety, tolerability, and pharmacokinetic data for ibuzatrelvir from a phase 1 first‐in‐human study in healthy adults. Study parts evaluated ibuzatrelvir as single or multiple ascending doses, including analysis of participants in fasted and fed states, pharmacokinetics in Chinese and Japanese participants, relative bioavailability of crystalline tablet formulations, and dose selection for patients with COVID‐19. Oral administration of ibuzatrelvir led to rapid absorption after all doses, and steady‐state plasma concentrations were achieved by Day 2 for all doses. High‐fat meals decreased maximum plasma concentration and area under the plasma concentration‐time curve from time 0 to the time of the last quantifiable concentration, but the concentration at 12 h postdose was comparable when administered without food. Exposures of ibuzatrelvir were similar between Chinese and non‐Chinese participants, as well as between Japanese and non‐Japanese participants. Ibuzatrelvir was safe and well‐tolerated, with no serious or severe adverse events reported and no participants discontinuing. In conclusion, pharmacokinetics and safety were established for single‐agent oral ibuzatrelvir, supporting the design and dose selection for further phase 2 trials and the continued development of ibuzatrelvir (NCT05580003).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsCOVID-19 Drug TreatmentSARS-CoV-2AdultFemaleHumansMaleMiddle AgedYoung AdultAdministration, OralBiological AvailabilityDose-Response Relationship, DrugHealthy Volunteers

Stichwörter der Autor:innen

infectious diseasepharmacokineticsphase Itherapeutic drug monitoring

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • Pfizer Research and Development, Cambridge, Massachusetts, USA.
  • Pfizer Research and Development, New York, New York, USA.
  • Pfizer Research and Development, Tadworth, UK.
  • Pfizer Research and Development, Groton, Connecticut, USA.

ORCID-Profile: Ravi Shankar P Singh, Frances Hackman, Mona Shahbazi, John Prybylski, Siddhee A Sahasrabudhe, Eugene P Kadar, Billy T George, Negar Niki Alami

Zitieren

APA

Singh, R. S. P., Toussi, S. S., Hackman, F., Shahbazi, M., Prybylski, J., Sahasrabudhe, S. A., Crownover, P., Kadar, E. P., George, B. T., Alami, N. N., & Bergman, A. (2026). A Multipart Phase 1 Study to Assess Safety and Pharmacokinetics of Ibuzatrelvir in Healthy Participants and Dose Selection for a Dose‐Ranging Study. Clinical and Translational Science. https://doi.org/10.1111/cts.70659

Vancouver

Singh RSP, Toussi SS, Hackman F, Shahbazi M, Prybylski J, Sahasrabudhe SA, et al. A Multipart Phase 1 Study to Assess Safety and Pharmacokinetics of Ibuzatrelvir in Healthy Participants and Dose Selection for a Dose‐Ranging Study. Clinical and Translational Science. 2026. doi:10.1111/cts.70659

BibTeX
@article{Singh2026,
  author = {Singh, Ravi Shankar P and Toussi, Sima S and Hackman, Frances and Shahbazi, Mona and Prybylski, John and Sahasrabudhe, Siddhee A and Crownover, Penelope and Kadar, Eugene P and George, Billy T and Alami, Negar Niki and Bergman, Arthur},
  title = {A Multipart Phase 1 Study to Assess Safety and Pharmacokinetics of Ibuzatrelvir in Healthy Participants and Dose Selection for a Dose‐Ranging Study},
  journal = {Clinical and Translational Science},
  year = {2026},
  doi = {10.1111/cts.70659}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche